Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

The purpose of this platform study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of novel RAS(ON) inhibitors as a monotherapy or combined with Standard(s) of Care (SOC) or with each other. The first four subprotocols include the following: Subprotocol A: RMC-6291 +/- RMC-6236 + SOC Subprotocol B: RMC-6236 + SOC Subprotocol C: RMC-9805 +/- RMC-6236 + SOC Subprotocol D: RMC-9805

Trial Details

NCT ID
NCT06162221
Phase
PHASE1 / PHASE2
Sponsor
Revolution Medicines, Inc.
Status
RECRUITING
Cancer Type
Non-Small Cell (NSCLC) Lung Cancer
Interventions
  • RMC-6291
  • RMC-6236
  • Pembrolizumab
  • Cisplatin
  • Carboplatin
  • Pemetrexed
Locations (sample)
  • Gilbert, Arizona, United States|33.35283,-111.78903
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Sacramento, California, United States|38.58157,-121.4944
  • San Diego, California, United States|32.71571,-117.16472

Key Eligibility Criteria

  • All Patients (unless otherwise noted):
  • ≥ 18 years of age
  • ECOG PS is 0 to 1
  • Adequate organ function as outlined by the study

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Non-Small Cell (NSCLC) Lung Cancer Trials on Trialify →